Skip to main content

Cerenome, Inc.

corporate_fare Company Profile

Cerenome, Inc.

CNSY·NASDAQ·Life Sciences·CIK 0001095981

CERENOME, INC. is a U.S. healthcare company that develops and sells precision diagnostics and targeted radiopharmaceuticals for cancers affecting the central nervous system (CNS). The company operates through its wholly owned subsidiary, CNSide Diagnostics, LLC, which focuses on developing and commercializing proprietary laboratory-developed tests. One such test is CNSide®, designed to detect tumor cells that have spread to the central nervous system in patients with carcinomas and melanomas. In the radiopharmaceuticals sector, CERENOME, INC.'s primary candidate is rhenium (186 Re) obisbemeda. This treatment is specifically developed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC). It is delivered directly and locally using approved standard-of-care tissue access methods like convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. The company also has an acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188 RNL-BAM), which is designed to treat various solid organ cancers, including primary and secondary liver cancers, through intra-arterial injection. CERENOME, INC. aims to overcome the limitations of traditional radiation therapy, such as long treatment durations, damage to healthy tissue, and insufficient radiation delivery. The company's radioactive drug formulations, medical devices, and therapeutic candidates are designed to deliver safe and effective radiation doses directly to tumors, potentially in a single treatment. This is achieved through innovative drug formulation approaches, including encapsulating radionuclides like rhenium isotopes within nanoliposomes and microspheres. These formulations are intended to increase patient-absorbed radiation doses and extend retention times, ensuring that the isotope clears after significant and essentially complete radiation decay, which contributes to less normal tissue/organ exposure and improved safety margins.

Cerenome, Inc. (NASDAQ:CNSY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for CNSY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for CNSY spans 8-K, 10-Q.

Recent high-impact activity:

  • Cerenome Reports Interim ReSPECT-LM Data: No Dose-Limiting Toxicity in First 10 Patients
  • Cerenome Posts First $0.7M Diagnostic Revenue but Cash Drops to $4.9M
  • Cerenome 10-Q: Going Concern Warning, Nasdaq Equity Deficiency After $8.7M Q3 Loss
  • Cerenome Posts First Diagnostic Revenue but Cash Falls to $4.9M
  • Aetna National Contract Adds 26M Members to CNSide Payer Footprint

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$5.21M
Net Income
-$22.39M
Diluted EPS
-$0.29
Op. Cash Flow
-$20.77M
Free Cash Flow
-$20.84M
Operating Income
-$15.3M
Cash & Equivalents
$4.26M
Debt / Equity
0.00×
Net Margin
-429.4%
Shares Outstanding
138.68M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-104258

Short Interest & Short Volume

14.87 days to cover

FINRA reported short interest of 844,013 shares in CNSY as of the October 30, 2026 settlement, a 7.9% increase from the prior period — about 14.9 days to cover at its recent average daily volume. On November 20, 2026, 61.2% of CNSY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)844,013 shares as of October 30, 2026
Change vs prior period▲ 7.9%
Days to cover14.87 at avg daily volume of 56,777
Daily short volume (FINRA facilities)61.2% of 124,780 shares on November 20, 2026
5-day average short volume43.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CNSY, detected from its recent SEC filings · based on capital-structure filings through 2026-09-10.

Convertible Note Financing Terms · Conversion Price and Dilution Risk

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$0.63 -0.02% today
52-week range · as of 2026-11-16 $0.4287 – $18.89
Market cap
$6.16M
Volume
256.7K (0.2× avg)
3-mo avg 1.6M
Live data · 2026-11-22 06:21 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CNSY - Latest Insights

CNSY
Nov 16, 2026, 7:45 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9629
Real-time Price: $0.630 info
Change: -$0.3329 (-35%) info
Market Cap: $6.16M info
CNSY
Nov 13, 2026, 5:19 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9601
Real-time Price: $0.630 info
Change: -$0.3301 (-34%) info
Market Cap: $6.16M info
CNSY
Nov 13, 2026, 5:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.970
Real-time Price: $0.630 info
Change: -$0.340 (-35%) info
Market Cap: $6.16M info
CNSY
Nov 13, 2026, 4:51 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9372
Real-time Price: $0.630 info
Change: -$0.3072 (-33%) info
Market Cap: $6.16M info
CNSY
Nov 04, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.31
Real-time Price: $0.630 info
Change: -$0.680 (-52%) info
Market Cap: $6.16M info
CNSY
Oct 08, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $0.630 info
Change: -$1.000 (-61%) info
Market Cap: $6.16M info
CNSY
Sep 30, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $0.630 info
Change: -$1.37 (-69%) info
Market Cap: $6.16M info
CNSY
Sep 22, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $0.630 info
Change: -$1.37 (-69%) info
Market Cap: $6.16M info
CNSY
Sep 10, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.61
Real-time Price: $0.630 info
Change: -$1.98 (-76%) info
Market Cap: $6.16M info
CNSY
Sep 10, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.69
Real-time Price: $0.630 info
Change: -$2.06 (-77%) info
Market Cap: $6.16M info
CNSY
Aug 14, 2026, 4:35 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.50
Real-time Price: $0.630 info
Change: -$2.87 (-82%) info
Market Cap: $6.16M info
CNSY
Aug 14, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.50
Real-time Price: $0.630 info
Change: -$2.87 (-82%) info
Market Cap: $6.16M info
CNSY
Aug 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.93
Real-time Price: $0.630 info
Change: -$3.30 (-84%) info
Market Cap: $6.16M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets